Latest Breaking News On - Ambrx biopharma company profile - Page 1 : comparemela.com

Ambrx Biopharma Inc (NYSE:AMAM) Given Consensus Rating of Moderate Buy by Analysts

Ambrx Biopharma Inc (NYSE:AMAM) Given Consensus Rating of Moderate Buy by Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Robertw bairdAmbrx biopharmaRenaissance technologiesAmbrx biopharma incB riley wealth advisors incRoyal bankCantor fitzgeraldAmbrx biopharma company profileGet free reportMarketbeat ratingsWealth advisorsExoduspoint capital managementGet freeBiopharma incAmbrx biopharma daily

Ambrx Biopharma Inc (NYSE:AMAM) Receives $24 13 Consensus Price Target from Brokerages

Ambrx Biopharma Inc (NYSE:AMAM) Receives $24 13 Consensus Price Target from Brokerages
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Ambrx biopharmaRobertw bairdCantor fitzgeraldHighvista strategiesAmbrx biopharma incRoyal bankSilverarc capital managementAmbrx biopharma company profileTd asset management incGet free reportMarketbeat ratingsBiopharma stock downManagement incPoint capital managementVista strategiesAsset management

Ambrx Biopharma Inc (NYSE:AMAM) Given Consensus Rating of Moderate Buy by Analysts

Ambrx biopharmaRobertw bairdExchange traded conceptsGoldman sachs groupInnovis asset managementRoyal bankChina universal asset management coSquarepoint opsAmbrx biopharma incAmbrx biopharma company profileGet free reportUniversal asset managementTraded conceptsAsset managementExoduspoint capital managementBiopharma stock down

B Riley Lowers Ambrx Biopharma (NYSE:AMAM) to Neutral

B. Riley downgraded shares of Ambrx Biopharma (NYSE:AMAM – Free Report) from a buy rating to a neutral rating in a research report report published on Tuesday, Marketbeat Ratings reports. B. Riley currently has $28.00 price objective on the stock, up from their previous price objective of $26.00. Several other brokerages have also recently commented […]

Ambrx biopharmaSonja nelsonDanielj oconnorRoyal bankAmbrx biopharma company profileDarwin global management ltdSecurities exchange commissionHermes incAmbrx biopharma incCantor fitzgeraldGoldman sachs groupFree reportMarketbeat ratingsModerate buyBiopharma stock downExchange commission

Commodore Capital LP Has $52 26 Million Holdings in Ambrx Biopharma Inc (NYSE:AMAM)

Commodore Capital LP lowered its position in shares of Ambrx Biopharma Inc. (NYSE:AMAM – Free Report) by 33.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,175,000 shares of the company’s stock after selling 1,628,447 shares during the period. […]

Ambrx biopharmaSonja nelsonCantor fitzgeraldRoyal bankAmbrx biopharma incB riley wealth advisors incSecurities exchange commissionSquarepoint opsAmbrx biopharma company profileRenaissance technologiesGoldman sachs groupCommodore capitalFree reportWealth advisorsExchange commissionCormorant asset management